Global Oncology Biosimilars Market Research Report 2019-2025
Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.
This report focuses on the global Oncology Biosimilars status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oncology Biosimilars development in United States, Europe and China.
In 2018, Global Oncology Biosimilars Market Size was XX Million USD and it is Expected to Reach XX million USD with a CAGR of XX% by the end of 2025.
Ask for Sample Copy of this Report:
https://www.orbisresearch.com/contacts/request-sample/2453720
This Research Report Categorizes the Global Oncology Biosimilars Market by Top Players/Brands, Region, Type and End User. This report also studies the global Oncology Biosimilars Market Status, Competition Landscape, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Sales Channels and Distributors.
Geographically, global Oncology Biosimilars market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; The Top Key Players includes Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD.
On the basis of Product Types, we research the production, revenue, price, market share and growth rate, primarily split into
mAb
Immunomodulators
Hematopoietic Agents
G-CSF
Others
For the End Users/Applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
For More Details: https://www.orbisresearch.com/contacts/enquiry-before-buying/2453720
Production, consumption, revenue, market share and growth rate are the key targets for Oncology Biosimilars from 2013 to 2024 (forecast) in these regions
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
If you have any special requirements, please let us know and we will offer you the report as you want.
To Get Reasonable Discount in this Report Click Here:
https://www.orbisresearch.com/contacts/discount/2453720
Table of Content:
Global Oncology Biosimilars Market Research Report 2019-2025
Chapter One: Study Coverage
Chapter Two: Executive Summary
Chapter Three: Breakdown Data by Manufacturers
Chapter Four: Breakdown Data by Product
Chapter Five: Breakdown Data by End User
Chapter Six: North America
Chapter Seven: Europe
Chapter Eight: Asia Pacific
Chapter Nine: Central & South America
Chapter Ten: Middle East and Africa
Chapter Eleven: Company Profiles
11.1 Celltrion
11.1.1 Celltrion Company Details
11.1.2 Company Business Overview
11.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Celltrion Oncology Biosimilars Products Offered
11.1.5 Celltrion Recent Development
11.2 Biocon
11.2.1 Biocon Company Details
11.2.2 Company Business Overview
11.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Biocon Oncology Biosimilars Products Offered
11.2.5 Biocon Recent Development
11.3 Dr. Reddy’s Laboratories
11.4 STADA Arzneimittel AG
11.5 Intas Pharmaceuticals
11.6 Pfizer
11.7 Sandoz International
11.8 Teva Pharmaceutical Industries Ltd
11.9 Apotex
11.10 BIOCAD
Chapter Twelve: Future Forecast
12.1 Oncology Biosimilars Market Forecast by Regions
12.2 Oncology Biosimilars Market Forecast by Product
12.3 Oncology Biosimilars Market Forecast by End User
12.4 North America Oncology Biosimilars Forecast
12.5 Europe Oncology Biosimilars Forecast
12.6 Asia Pacific Oncology Biosimilars Forecast
12.7 Central & South America Oncology Biosimilars Forecast
12.8 Middle East and Africa Oncology Biosimilars Forecast
Chapter Thirteen: Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
Chapter Fourteen: Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Oncology Biosimilars Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: sales@orbisresearch.com
Your information will never be shared with any third party.